Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 7;16(1):269.
doi: 10.1186/s13256-022-03456-x.

Chlordiazepoxide-induced delirium in a patient undergoing alcohol withdrawal: a case report

Melissa A Arabadjief  1 , Omar H Elsayed  1 , Sabina Bashir  1 , Meenakshi R Gundumalla  1 , Derek S Menefee  1 , Cody L Bergman  1 , Nayeem Z Moulana  1 , Rif S El-Mallakh  2
Affiliations
Case Reports

Chlordiazepoxide-induced delirium in a patient undergoing alcohol withdrawal: a case report

Melissa A Arabadjief et al. J Med Case Rep. .

Abstract

Background: Ethanol dependence is associated with a discontinuation withdrawal delirium. Chlordiazepoxide is frequently successfully used in its treatment.

Case presentation: A 27-year-old, Caucasian female with ethanol dependence who had objective symptoms of withdrawal experienced worsening of her delirium after administration of chlordiazepoxide, but improved with lorazepam and cleared with discontinuation of benzodiazepine administration.

Conclusions: Worsening of delirium appears to be related to the specific use of chlordiazepoxide, but the mechanism of this effect is not clear. While this case does not alter the standard care of ethanol dependence, it does alert clinicians that our treatment approach may not be fully benign.

Keywords: Acetylcholine; Alcohol withdrawal; Benzodiazepine; Case report; Chlordiazepoxide; Delirium tremens; Ethanol withdrawal.

PubMed Disclaimer

Conflict of interest statement

There are no actual competing interests for this paper. However, Dr. El-Mallakh serves as a speaker for Indivior, Intracellular Therapies, Janssen, Lundbeck, Noven, Otsuka, Sunovion, and Teva. None of the other authors has any actual or perceived competing interests.

References

    1. Vasilevskis EE, Han JH, Hughes CG, Ely EW. Epidemiology and risk factors for delirium across hospital settings. Best Pract Res Clin Anaesthesiol. 2012;26:277–287. doi: 10.1016/j.bpa.2012.07.003. - DOI - PMC - PubMed
    1. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens) N Engl J Med. 2014;371(22):2109–2113. doi: 10.1056/NEJMra1407298. - DOI - PubMed
    1. Grover S, Ghosh A. Delirium tremens: assessment and management. J Clin Exp Hepatol. 2018;8(4):460–470. doi: 10.1016/j.jceh.2018.04.012. - DOI - PMC - PubMed
    1. Perälä J, Kuoppasalmi K, Pirkola S, Härkänen T, Saarni S, Tuulio-Henriksson A, et al. Alcohol-induced psychotic disorder and delirium in the general population. Br J Psychiatry. 2010;197(3):200–206. doi: 10.1192/bjp.bp.109.070797. - DOI - PubMed
    1. Lonergan E, Luxenberg J, Areosa Sastre A. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;2009(4):CD006379. doi: 10.1002/14651858.CD006379.pub3. - DOI - PMC - PubMed

Publication types